Acute hematogenous musculoskeletal infection is a common cause of pediatric hospitalization and is routinely treated with prolonged antibiotic therapy [1] [2] [3] [4] [5] [6] . Provider-dependent practice variations in the care of these patients exist and might contribute to increased numbers of adverse events, lengths of hospitalization, expenses to hospitals and families, and discord among treatment teams [6] [7] [8] . Locally developed clinical care guidelines (CCGs) are effective tools for helping to standardize care and limit practice variations [7, [9] [10] [11] . To address practice variations for patients with musculoskeletal infection at Children's Hospital Colorado (CHCO), a multidisciplinary CCG was developed and implemented in 2012 (Table 1; see  Supplementary Text) .
To assess the effect or quality of care of the CHCO guideline on patients, data were examined retrospectively to compare the pre-CCG and post-CCG time periods according to length of stay (LOS), overall antibiotic use, and multiple secondary clinical, process, and therapeutic end points.
MATERIALS AND METHODS
A single-center retrospective study was performed at CHCO, a freestanding 444-bed quaternary care hospital. The Colorado Multiple Institutional Review Board approved this project.
In September 2011, a multidisciplinary team of key stakeholders formed a committee aimed at developing a CCG for previously healthy hospitalized children with acute musculoskeletal infection. The committee used evidence when available and consensus when needed to develop the guideline; committee participants included representatives from orthopedics, infectious diseases, hospitalist medicine, emergency medicine, radiology, and pharmacy. The CCG was implemented in July 2012. Providers and housestaff were educated about the CCG, and a specific musculoskeletal order set was added to the electronic medical record (EMR). After implementation, the committee met regularly as champions of the guideline for continued optimization and compliance monitoring.
For this study, pre-CCG (June 2009 through June 2011) and post-CCG (September 2012 through June 2014) cohorts were compared. The intervening period (July 2011 through August 2012) was excluded because guideline discussions might have otherwise influenced care. Children were included if they were at least 6 months but younger than 18 years of age on the date of arrival and had a discharge diagnosis code of acute osteomyelitis (International Classification of Diseases, Ninth Revision [ICD-9] codes 730.00-730.09 or 730. 20-730.29) , septic arthritis (ICD-9 codes 711.00-711.09), and/or pyomyositis (ICD-9 codes 728.0, 728.19, or 040.81). Hospital chart documentation from admitting providers was reviewed by the investigators for exclusion criteria. Children who had postoperative infection or chronic infection (ie, >2 weeks of symptoms), were readmitted after recent musculoskeletal treatment, perforating injury/ trauma, a severe comorbid condition (such as a rheumatologic diagnosis, an immunosuppressive condition, spina bifida, or cerebral palsy), were treated initially at an outside hospital, had osteomyelitis of the head/orbits, or had primary central nervous system infection were excluded.
Two unblinded trained reviewers extracted data from the EMR retrospectively. Collected data from each inpatient admission included patient demographics, diagnosis details (including location[s], tissue[s] infected and abscessed, and number of foci), antibiotic(s) received, LOS from hour of arrival at CHCO to hour of discharge, C-reactive protein (CRP) level(s), related readmission(s), length of fever (≥38.2°C, in hours), culture source(s), timing, and results, presence of either persistent (positive culture result from blood drawn 24 hours after initiation of any antimicrobial) or transient (positive culture result without repeat positive after 24 hours of antimicrobial therapy) bacteremia, central line placement, and specialty service(s) consulted. Collected data from outpatient follow-up included disease-related readmission(s), total length of antimicrobial treatment, days to a CRP of <2 mg/dL for patients in whom CRP values were followed in the CHCO EMR (exact values in outside systems were not recorded reliably), and length of outpatient follow-up. To assess the extent of each infection and ensure that no difference in pre-CCG and post-CCG existed in that regard, we developed an a priori definition for the extent of infection; the total number of diagnoses assigned to each patient were added (up to 5, for osteomyelitis, septic arthritis, pyomyositis, abscess, and/or persistent bacteremia). Antibiotic-use data were collected as length of therapy (LOT) and days of therapy (DOT). For example, data for a patient on 2 antimicrobials for 5 days were recorded as 5 LOT and 10 DOT [12] . The primary outcomes were LOS and length and days of intravenous antimicrobial therapy. Secondary outcomes focused on additional clinical, process, and therapeutic end points. Data were entered in the CHCO REDCap database.
Cultures of blood and source samples were performed in the microbiology laboratory at CHCO using Clinical and Laboratory Standards Institute break points for susceptibility. For Staphylococcus aureus at our institution, clindamycin-inducible resistance is routinely evaluated. Kingella kingae polymerase chain reaction (PCR) was not available during the study period. The causative pathogen was defined as a pathogen recovered from any blood or source culture that was intentionally treated by the provider who was caring for the patient.
Statistical analysis included adjustment for the extent of infection when applicable, although both adjusted and unadjusted values are presented. The distributions of continuous variables were assessed; most of them were not normally distributed, so nonparametric statistics are reported when possible. The Kruskal-Wallis test was used to compare continuous outcomes before and after CCG implementation. The χ 2 or Fisher exact test was used to compare categorical outcomes, and the log-rank test was used for time-to-event outcomes. For time to first antibiotic and time to first blood culture, a negative value was possible if the patient was started on antibiotics or had a blood culture before arrival at the hospital; such patients were excluded from the survival analysis, but included in Table 4 . For the length-of-fever outcome, patients who remained afebrile were excluded, and the log-rank test was used for an unadjusted comparison of the pre-CCG and post-CCG groups; a Cox proportional hazards model was used to compare the groups while adjusting for extent of infection. To compare inpatient CRP levels decreases, the number of days between arrival and date of CRP result was calculated for each daily peak CRP value. To compare the rate of change in CRP levels, a random-coefficients mixed-effects model was fit to the CRP data with days since arrival treated as a continuous variable. An interaction term between days and group was included in the model. The Kruskal-Wallis test was used to compare the number of CRP tests per patient. The log-rank test was used to compare the number of days to a CRP level of <2 mg/dL.
RESULTS

Overview
ICD-9 codes identified 426 patient encounters with a diagnosis of osteomyelitis, septic arthritis, or pyomyositis; 262 patients met exclusion criteria (Figure 1) , which left 164 patients in the analysis, coincidently 82 in the pre-CCG group and 82 in the post-CCG group.
Patient demographics were not significantly different between the pre-CCG and post-CCG groups ( Table 2) . We found no statistically significant differences in the extent of infection between the pre-CCG and post-CCG patients when assessed as a continuous variable, and although twice as many patients in the post-CCG group than in the pre-CCG group had 3 or more assigned diagnoses (18 vs 9, The total is greater than 164 because several patients had both OM and SA. Of the 164 patients, 90 had osteomyelitis alone, 43 had septic arthritis alone, 17 had both septic arthritis and osteomyelitis, and 14 patients had pyomyositis alone.
respectively), this result was not significant (P = .058). Of the 164 included patients, 90 had osteomyelitis, 43 had septic arthritis, and 17 had combined osteomyelitis and septic arthritis. Fourteen patients had pyomyositis with no bone or joint involvement (Table 3 ). Twenty pre-CCG patients and 17 post-CCG patients had uncomplicated osteomyelitis (ie, no associated abscess or pyomyositis), and 18 pre-CCG and 12 post-CCG patients had uncomplicated septic arthritis.
Regions of diagnoses and number of each diagnosis for the group as a whole (osteomyelitis, septic arthritis, pyomyositis, and abscess) were not different between the 2 groups. The numbers of patients with persistent bacteremia were equal in both groups (6 each).
Primary Outcomes
Compared to those in the pre-CCG group, patients in the post-CCG cohort had a 0.6-day-shorter LOS (median, 5.56 vs 4.94, respectively; P = .04 [P = .16, unadjusted]), a 4.9-day-shorter LOT (median, 8.3 vs 3.4 days, respectively; P < .0001), and 6.4-day-fewer DOT (median, 10.2 vs 3.8 days, respectively; P < .0002) ( Table 4) .
Secondary Outcomes
Regarding clinical outcomes, the median length of fever was decreased by 24.5 hours after implementation of the CCG (P = .012), and this result did not depend on whether a patient underwent a procedure (P = .019) (Figure 2 ; Tables 4 and 5 ). The rates of CRP decline while inpatient were similar in both groups (P = .78) ( Figure 3A) , although time to a CRP level of <2.0 mg/ dL for those with values in our EMR was reduced by 4 days in the post-CCG cohort (P < .0001) ( Figure 3B ). Of the patients who had blood drawn for laboratory testing on admission, 53% had a white blood cell count of ≥10 000 cells/μL, but only 20% had a count of ≥15 000 cells/μL. Of those whose inflammatory markers were tested on admission, 80% had an erythrocyte-sedimentation rate of ≥20 mm/hour, and 69% had a rate of ≥30 mm/hour; 86% had a CRP level of ≥2 mg/dL, and 70% had a level of ≥4 mg/ dL [13] [14] [15] . The lengths of follow-up were similar between the groups (median, 49 and 42 days [pre-CCG and post-CCG groups, respectively]; P = .15), although fewer patients were lost to follow-up in the post-CCG group (11 patients were lost before the CCG and 3 patients were lost after the CCG; P = .03). Related readmissions were decreased by 50% in the post-CCG group (10 vs 5, respectively; P = .03); of these readmissions, 3 in the pre-CCG group and 1 in the post-CCG group were attributable to perceived therapeutic failure. Additional reasons for related readmissions were central line complication (3 pre-CCG No patients in either cohort were admitted directly to the pediatric intensive care unit; however, subsequent transfer to the pediatric intensive care unit occurred for 6 patients in the pre-CCG group and 3 patients in the post-CCG group (Table 5) . Antimicrobial-use outcomes were different between the groups (Table 4) . Intravenous antibiotics were given to all 164 patients, and the median times to receipt of first antimicrobial (0.5 pre-CCG vs 0.75 days post-CCG; P = .31) did not change significantly despite CCG encouragement to delay antibiotics until source cultures were performed. We found no statistical significance between the 2 groups for total duration of antimicrobial therapy (intravenous [iv] and oral); however, in addition to the decreased LOT and DOT observed in the primary outcomes, fewer total days of iv antimicrobials (1155 vs 489 days, respectively) and vancomycin (104 vs 59 days, respectively) were given after CCG implementation than before it, and fewer central lines were placed (42 [51%] vs 14 [17%], respectively; P < .0001). However, vancomycin was initiated in more patients (25 in the pre-CCG group vs 35 in the post-CCG group). The most commonly used iv antimicrobials among both groups were cefazolin (67% of all patients) and clindamycin (54%).
From a descriptive standpoint, the number of patients who underwent specialty consultation from a pediatric infectious disease specialist increased (80% before the CCG vs 97% after the CCG; P = .0005,) whereas the numbers of orthopedics consults remained similar (93% before the CCG vs 96% after the CCG; P = .72). No differences were found in the numbers of magnetic resonance imaging scans (data not shown) or operating room visits and procedures (Table 5) .
Culture Collection and Pathogen Identification
The times to first blood culture and rates of pathogen identification between the cohorts were also compared, as were the pathogens identified (Tables 4, 5 and 6; Figure 4 ). More patients in the post-CCG group had blood cultures performed before antibiotics, and more of them had a source culture performed (Table 5 ). The overall rate of a patient having a positive culture (blood, source, or both) improved after CCG implementation, although this result was not significant (67% before the CCG vs 79% after the CCG; P = .056). Blood culture results were positive in 48% of patients in the post-CCG group but only 39% in the pre-CCG group. It should be noted that in both groups, 28% to 29% of the patients had a causative pathogen determined from only a source culture (Table 5) . Of the 120 patients with an identified pathogen, the pathogen profiles did not change in the time before to after CCG implementation (Table 6 ). With the pre-CCG and post-CCG groups together, 81% of 120 positive cultures identified S aureus, of which 12% were MRSA. All MRSA isolates were susceptible to clindamycin. Of the 85 MSSA isolates, 7 (8%) were resistant to clindamycin. After S aureus, Streptococcus pyogenes was the most common pathogen, followed by Streptococcus pneumoniae, and K kingae. K kingae accounted for only 2 isolates, although it should be noted that we did not use PCR during the study time period.
DISCUSSION
In July 2012, CHCO implemented a CCG for acute hematogenous musculoskeletal infection to help limit practice variations and improve care. After CCG implementation, all primary outcomes improved, and we found significant decreases in hospital LOS, days of iv antibiotic therapy, and length of iv antibiotic therapy (Table 4 ). This study resulted in the shortest median LOS and among the shortest median iv DOT and LOT described; it should be noted that we did not exclude patients with extensive infection or prolonged LOS [7, [14] [15] [16] [17] [18] [19] [20] . Secondary outcomes for clinical, process, and therapeutic measures were also uniformly favorable in the post-CCG group. Implementation of a CCG for acute musculoskeletal infection improves processes and decreases use of resources while improving patient care and outcomes. After CCG implementation, the percentage of children with an identified pathogen was 79%, a yield higher than that in other reports [21] [22] [23] [24] [25] [26] [27] . This high percentage was achieved with a combination of source cultures, which provided the only positive culture in 28% to 29% of the patients in whom a pathogen was identified and increased timely blood culture results; 95% of the patients had a blood culture performed within 11 hours of arrival in the post-CCG group, whereas it took 45 hours in the pre-CCG group (Figure 4) . After CCG implementation, fewer patients in the post-CCG group underwent a surgical procedure after which providers failed to send a sample for culture than in the pre-CCG group (2 vs 13, respectively; P = .007) ( Table 5) . By identifying the causative pathogen, providers are better able to target antimicrobial therapy [25] . In 27% of the patients overall (33% before the CCG and 20% after the CCG), no pathogen was identified. In Figure 4 . Days to first blood culture. Patients for whom a blood culture was not performed were excluded, as were patients for whom a blood culture was performed before presentation, leaving 61 of 82 patients in the pre-clinical care guideline (CCG) group and 55 of 82 patients in the post-CCG group for evaluation (P = .019, adjusted). The 95th percentile for days to first blood culture was 1.88 in the pre-CCG group, 0.46 in the post-CCG group, and 1.04 overall. those whose pathogen was identified, the causative agents in the pre-CCG and post-CCG groups did not change; S aureus predominated (81% of the 120 patients with a positive culture result), which is similar to the results of other epidemiologic studies of acute musculoskeletal infection in children [24, 28, 29] (Table 6 ). It is interesting to note that at CHCO, 26% to 35% of overall S aureus isolates are MRSA (on the basis of 2009-2014 antibiograms); however, in this population, only 12% of S aureus isolates were MRSA. In addition, in 2014 at CHCO, 77% of all MRSA isolates and 81% of MSSA isolates were susceptible to clindamycin, whereas 100% of MRSA isolates and 92% of MSSA isolates in this study population were susceptible to clindamycin. K kingae accounted for only 2 isolates, which is in contrast to recent literature stating that it rivals S aureus in younger age groups. However, because we did not use a K kingae-specific PCR assay during the study period, some of the 44 patients with an unidentified pathogen might have had disease attributable to K kingae [22, [30] [31] [32] [33] [34] ; 18 (41%) of these 44 patients were younger than 5 years, the population most affected by K kingae [35] . The results of this study show that identifying a pathogen nearly 80% of the time in the case of acute pediatric musculoskeletal infection is achievable and contributes to improved care. Our CCG encourages culturing the source of infection before initiation of antimicrobials and recommends delaying antimicrobials in stable patients until a specimen can be obtained, which is a relatively progressive recommendation. However, recent literature suggests that pretreatment does not decrease culture yield [26, 27] . In reevaluating our process in light of this literature, our working group continues to recommend that a source culture be performed before administering antibiotics, stating that a "clean" negative might prevent unnecessary or excessively broad antimicrobials in these patients (not examined in other studies) [25] , and the pathology occasionally leads to another diagnosis [36] . For example, an untreated culture-negative source sample and pathology suggested a diagnosis of chronic nonbacterial osteomyelitis in 3 patients (excluded from study for alternative diagnosis), all of whom remained without antibiotics and did well with anti-inflammatory medication.
As was suggested in more recent literature, a faster transition to oral antibiotics for patients with acute musculoskeletal infection is not only safe but also decreases the number of complications associated with central lines and adverse parenteral antibiotic effects [8, 19, 25, [37] [38] [39] [40] [41] [42] [43] . Our CCG emphasizes clinical parameters for transition from intravenous to oral antibiotics based on fever resolution, improving CRP levels, and improved clinical examination. Under the CCG, children were switched even if transiently bacteremic; this group was larger in the post-CCG period than before CCG implementation (40% vs 33%, respectively), likely because of the increase in blood culture obtainment (Table 5 ). Given the typical pathogenesis for acute musculoskeletal infection in children is via hematogenous seeding of a bone or joint, all patients are theoretically bacteremic during their course, and capturing this information might have as much to do with the timing and quality of blood culture as with the extent of disease [18, 44, 45] . This clinically based transition to oral antibiotics decreased intravenous antibiotic use without compromising outcomes. The median length of total antimicrobial therapy (intravenous plus oral) was more than 44 days for both groups. On the basis of some literature, shorter courses of therapy might be possible [14, 15, 39, 40, 46] . However, in a comparison of the extent of disease in our population at CHCO to that in these other studies, relatively few of our patients had isolated osteomyelitis or septic arthritis [39, 40] ; now that care is standardized, shorter courses for our population might be explored in the future.
After CCG implementation, we found increased rates of infectious disease and orthopedics consultation. After the CCG was implemented, the orthopedic surgery and infectious diseases departments have a mutually agreed-on resource and now attend rounds on patients together, which has led to improved care and professional collaboration.
There are several limitations in and areas for future improvement for this study. First, the study was not prospective or randomized, and care might have changed over time as a result of factors unrelated to the CCG. Second, data on adverse drug events and central line complications after discharge were collected from our EMRs and did not include adverse drug events or central line complications in patients seen elsewhere after discharge. However, adverse events in patients with a central line have been reported to have a rate as high as 30% [8] . Third, this study was performed at a single center, and although the results indicate improved quality of care at CHCO, these findings might not be widely applicable.
In summary, in an attempt to decrease provider variability in the care of patients with acute musculoskeletal infection, a multidisciplinary CCG was developed at CHCO that prioritized identification of a causative pathogen and tailored antibiotic therapy and clinical parameters for transition to oral antimicrobials regardless of the presence of bacteremia. After implementation of this guideline, we found statistically significant decreases in length of hospitalization and exposure to antibiotics and improved patient outcomes with no adverse effects. Implementation of an acute musculoskeletal infection CCG results in improved patient outcomes and decreased exposure to antimicrobials. These findings offer insight into the standard of care for treatment of acute hematogenous musculoskeletal infection in pediatric patients.
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